Provided by Tiger Trade Technology Pte. Ltd.

89Bio, Inc.

14.84
0.0000
Volume:- -
Turnover:825.47M
Market Cap:2.20B
PE:-4.35
High:14.84
Open:14.84
Low:14.84
Close:14.84
52wk High:15.06
52wk Low:4.16
Shares:148.31M
Float Shares:103.73M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4140
EPS(LYR):-3.5055
ROE:-86.86%
ROA:-49.10%
PB:4.22
PE(LYR):-4.23

Loading ...

Company Profile

Company Name:
89Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.